Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of BAL0891 as Monotherapy and in Combination With Chemotherapy or Tislelizumab in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

NCT05768932 is registered in ClinicalTrials.gov with SillaJen, Inc. as lead sponsor.

NCT NCT05768932
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05768932 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of BAL0891 as Monotherapy and in Combination With Chemotherapy or Tislelizumab in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Lead sponsor
SillaJen, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
December 14, 2022
Completion date
December 24, 2026
Enrollment
260 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, gastric cancer, leukemia acute myeloid leukemia (aml), tnbc - triple-negative breast cancer